Source and scope
This summary is bounded to the recommendations, population and decisions covered by Glycemic Management Across the Lifespan for People With Type 1 Diabetes: A Clinical Practice Guideline. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:Diabetes Canada type 1
Source-attributed clinical priorities
- Use physiologic insulin replacement with structured glucose monitoring and individualized education; never stop basal insulin during illness.
- Teach hypoglycemia prevention and sick-day ketone management, with urgent assessment for suspected diabetic ketoacidosis.
- Screen systematically for microvascular, cardiovascular, autoimmune and psychosocial complications using the current Canadian guideline.
- Ensure access to glucose and ketone monitoring, insulin supplies, glucagon and structured education.
sources for this section:Diabetes Canada type 1
Practical assessment and management workflow
1
Confirm diabetes type and assess insulin regimen, technology, hypoglycemia, nutrition and injection sites.
2
Set individualized glucose and A1C goals and align basal, mealtime and correction insulin with daily life.
3
Review sick-day rules, exercise, driving, alcohol and pregnancy planning at appropriate visits.
4
Screen eyes, kidneys, feet, thyroid, celiac disease and cardiovascular risk on the Canadian schedule.
sources for this section:Diabetes Canada type 1
Safety, red flags and urgent escalation
- Never stop basal insulin during illness; check ketones and escalate vomiting or acidosis symptoms.
- Treat severe hypoglycemia immediately and review cause, awareness and driving safety afterward.
- Have a perioperative and hospital insulin plan to prevent omission and ketoacidosis.
sources for this section:Diabetes Canada type 1
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:Diabetes Canada type 1
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:Diabetes Canada type 1
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Diabetes CanadaGlycemic Management Across the Lifespan for People With Type 1 Diabetes: A Clinical Practice GuidelineDOI 10.1016/j.jcjd.2025.01.001 路 Can J Diabetes 2025;49(1):5-18; addendum DOI 10.1016/j.jcjd.2025.04.010 路 accessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.